Plant ID: NPO14130
Plant Latin Name: Phagnalon rupestre
Taxonomy Genus: Phagnalon
Taxonomy Family: Asteraceae
NCBI TaxonomyDB:
943712
Plant-of-the-World-Online:
n.a.
Israel; Jordan
FFAR4; FFAR1; | |
CA7; CA4; | |
PPARA; | |
ALOX15; CBR1; AKR1B10; AKR1B1; | |
XDH; | |
LMNA; FABP3; FABP5; |
Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
---|---|---|---|---|
Cytochrome P450 family 1 | CYP1B1 | Cytochrome P450 1B1 | Q16678 | CHEMBL4878 |
Cytochrome P450 family 1 | CYP1A1 | Cytochrome P450 1A1 | P04798 | CHEMBL2231 |
Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
Cytochrome P450 family 19 | CYP19A1 | Cytochrome P450 19A1 | P11511 | CHEMBL1978 |
Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
Enzyme_unclassified | CBR1 | Carbonyl reductase [NADPH] 1 | P16152 | CHEMBL5586 |
Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
Lyase | CA7 | Carbonic anhydrase VII | P43166 | CHEMBL2326 |
Lyase | CA4 | Carbonic anhydrase IV | P22748 | CHEMBL3729 |
Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
Small molecule receptor (family A GPCR) | FFAR4 | G-protein coupled receptor 120 | Q5NUL3 | CHEMBL5339 |
Small molecule receptor (family A GPCR) | FFAR1 | Free fatty acid receptor 1 | O14842 | CHEMBL4422 |
Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|
MF | GO:0005488; binding | GO:0005506; iron ion binding | 6.912E-11 | 3.763E-07 | ALOX15, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19, XDH |
BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 1.104E-10 | 4.008E-07 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0005488; binding | GO:0019825; oxygen binding | 4.570E-10 | 9.047E-07 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 1.450E-09 | 2.255E-06 | AKR1B1, AKR1B10, CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.127E-09 | 4.256E-06 | CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 4.622E-09 | 5.440E-06 | CYP19A1, CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0020037; heme binding | 9.445E-08 | 8.227E-05 | CYP19A1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0017144; drug metabolic process | 2.685E-07 | 2.016E-04 | AKR1B1, AKR1B10, CBR1, CYP1A1, CYP1A2, CYP1B1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0009404; toxin metabolic process | 1.189E-06 | 7.848E-04 | CYP1A1, CYP1A2, CYP1B1 |
MF | GO:0005488; binding | GO:0005504; fatty acid binding | 1.960E-06 | 1.185E-03 | FABP3, FABP5, FFAR4 |
MF | GO:0003824; catalytic activity | GO:0009055; electron transfer activity | 2.662E-06 | 1.526E-03 | AKR1B1, CYP19A1, CYP1A2, XDH |
MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 3.993E-06 | 2.121E-03 | CYP19A1, CYP1A1, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0018894; dibenzo-p-dioxin metabolic process | 4.916E-06 | 2.489E-03 | CYP1A1, CYP1A2 |
MF | GO:0003824; catalytic activity | GO:0016903; oxidoreductase activity, acting on the aldehyde or oxo group of donors | 8.786E-06 | 4.232E-03 | AKR1B1, AKR1B10, XDH |
BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 1.228E-05 | 5.687E-03 | CYP1A2, CYP2C19 |
BP | GO:0008152; metabolic process | GO:0022900; electron transport chain | 1.331E-05 | 6.038E-03 | AKR1B1, CYP19A1, CYP1A2, XDH |
BP | GO:0008152; metabolic process | GO:0044242; cellular lipid catabolic process | 1.724E-05 | 7.508E-03 | AKR1B10, CYP1B1, FABP3, FABP5 |
BP | GO:0008152; metabolic process | GO:0044597; daunorubicin metabolic process | 2.289E-05 | 8.900E-03 | AKR1B1, AKR1B10 |
BP | GO:0008152; metabolic process | GO:0044598; doxorubicin metabolic process | 2.289E-05 | 8.900E-03 | AKR1B1, AKR1B10 |
BP | GO:0008152; metabolic process | GO:0050665; hydrogen peroxide biosynthetic process | 2.289E-05 | 8.900E-03 | CYP1A1, CYP1A2 |
Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
---|---|---|---|---|---|---|
09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 8.412E-09 | 2.860E-07 | CBR1, CYP1A2, CYP1A1, CYP1B1, CYP2C19 |
Unclassified | Unclassified | hsa01100 | Metabolic pathways | 3.812E-07 | 4.087E-06 | CBR1, AKR1B10, CYP1A2, ALOX15, CYP1A1, AKR1B1, CYP2C19, CYP19A1, XDH |
09100 Metabolism | 09103 Lipid metabolism | hsa00140 | Steroid hormone biosynthesis | 1.890E-07 | 3.213E-06 | CYP1A2, CYP1A1, CYP1B1, CYP19A1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 4.808E-07 | 4.087E-06 | CBR1, CYP1A2, CYP1A1, CYP1B1 |
09100 Metabolism | 09105 Amino acid metabolism | hsa00380 | Tryptophan metabolism | 5.923E-06 | 3.356E-05 | CYP1A2, CYP1A1, CYP1B1 |
09150 Organismal Systems | 09152 Endocrine system | hsa04913 | Ovarian steroidogenesis | 1.168E-05 | 4.966E-05 | CYP1A1, CYP1B1, CYP19A1 |
09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 2.204E-06 | 1.499E-05 | CYP1A2, ALOX15, CYP2C19 |
09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 2.239E-05 | 8.460E-05 | CBR1, ALOX15, CYP2C19 |
09150 Organismal Systems | 09152 Endocrine system | hsa03320 | PPAR signaling pathway | 3.090E-05 | 1.051E-04 | FABP3, FABP5, PPARA |
09100 Metabolism | 09103 Lipid metabolism | hsa00561 | Glycerolipid metabolism | 1.270E-03 | 2.878E-03 | AKR1B10, AKR1B1 |
09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.539E-03 | 3.270E-03 | CYP1A2, CYP1A1 |
09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 1.732E-03 | 3.464E-03 | CYP1A2, CYP2C19 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00040 | Pentose and glucuronate interconversions | 4.733E-04 | 1.149E-03 | AKR1B10, AKR1B1 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 3.279E-04 | 9.289E-04 | AKR1B10, AKR1B1 |
09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 4.485E-03 | 8.471E-03 | ALOX15, CYP2C19 |
09100 Metabolism | 09101 Carbohydrate metabolism | hsa00051 | Fructose and mannose metabolism | 3.734E-04 | 9.767E-04 | AKR1B10, AKR1B1 |
09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 1.032E-04 | 3.190E-04 | CA4, CA7 |
09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 7.638E-06 | 3.710E-05 | CYP1A2, XDH |
ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
---|---|---|---|
H00-H59: Diseases of the eye and adnexa | Ocular hypertension | H40.0 | CA4; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic cataract | E10.36, E11.36 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic complication | E08-E13 | AKR1B1; |
I00-I99: Diseases of the circulatory system | Heart failure | I50 | XDH; |
C00-D49: Neoplasms | Hormonally-responsive breast cancer | C50 | CYP19A1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricemia | E79.0 | XDH; |
G00-G99: Diseases of the nervous system G00-G99 | Encephalopathy | G93.4 | XDH; |
E00-E89: Endocrine, nutritional and metabolic diseases | Hyperuricaemia in gout | E79.0, M10 | XDH; |
J00-J99: Diseases of the respiratory system | Asthma | J45 | CBR1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetic neuropathy | E11.40 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | AKR1B1; FFAR1; |
C00-D49: Neoplasms | Breast cancer | C50 | CYP19A1; |
N00-N99: Diseases of the genitourinary system | Endometriosis | N80 | CYP19A1; |
H00-H59: Diseases of the eye and adnexa | Open-angle glaucoma | H40-H42 | CA4; |
C00-D49: Neoplasms | Bladder cancer | C67 | CYP19A1; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Gout | M10 | AKR1B1; XDH; |
M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | FFAR1; |
C00-D49: Neoplasms | Head and neck cancer | C07-C14, C32-C33 | AKR1B1; |
N00-N99: Diseases of the genitourinary system | Prostate disease | N42.9 | CYP19A1; |
C00-D49: Neoplasms | Advanced breast cancer | C50 | CYP19A1; |
H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | AKR1B1; |
E00-E89: Endocrine, nutritional and metabolic diseases | Non-insulin dependent diabetes | E11.9 | FFAR1; |